AHA 2022 – Idorsia and Cincor move forward in hypertension
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
ESGCT 2022 – Sangamo strengthens its case in Fabry
The group looks like the gene therapy contender to beat, but that is not saying much.
The lowdown on high blood pressure
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
Go or no go? Roche’s fresh start for a new year
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.